↓ Skip to main content

PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer

Overview of attention for article published in Molecular Cancer Therapeutics, April 2011
Altmetric Badge

Mentioned by

facebook
1 Facebook page

Citations

dimensions_citation
150 Dimensions

Readers on

mendeley
64 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer
Published in
Molecular Cancer Therapeutics, April 2011
DOI 10.1158/1535-7163.mct-10-1089
Pubmed ID
Authors

A. M. Gonzalez-Angulo, J. Ferrer-Lozano, K. Stemke-Hale, A. Sahin, S. Liu, J. A. Barrera, O. Burgues, A. M. Lluch, H. Chen, G. N. Hortobagyi, G. B. Mills, F. Meric-Bernstam, Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, Sahin A, Liu S, Barrera JA, Burgues O, Lluch AM, Chen H, Hortobagyi GN, Mills GB, Meric-Bernstam F

Abstract

The purpose of this work was to determine whether there are differences in PIK3CA mutation status and PTEN protein expression between primary and matched metastatic breast tumors as this could influence patient management. Paraffin sections of 50 μm were used for DNA extraction and slides of 3 μm for immunohistochemistry (IHC) and FISH. Estrogen receptor, progesterone receptor, and HER2 IHC were repeated in a central laboratory for both primary tumors and metastases. PTEN levels were assessed by IHC and phosphoinositide 3-kinase (PI3K) pathway mutations were detected by a mass spectroscopy-based approach. Median age was 48 years (range: 30-83 years). Tumor subtype included 72% hormone receptor positive/HER2 negative, 20% HER2-positive, and less than 7.8% triple receptor negative. Tissues were available for PTEN IHC in 46 primary tumors and 52 metastases. PTEN was lost in 14 (30%) primary tumors and 13 (25%) metastases. There were five cases of PTEN loss and eight cases of PTEN gain from primary tumors to metastases (26% discordance). Adequate DNA was obtained from 46 primary tumors and from 50 metastases for PIK3CA analysis. PIK3CA mutations were detected in 19 (40%) of primary tumors and 21 (42%) of metastases. There were five cases of PIK3CA mutation loss and four cases of mutation gain (18% discordance). There was an increase of the level of PIK3CA mutations in four cases and decrease in one case from primary tumors to metastases. There is a high level of discordance in PTEN level, PIK3CA mutations, and receptor status between primary tumors and metastases that may influence patient selection and response to PI3K-targeted therapies.

Mendeley readers

The data shown below were compiled from readership statistics for 64 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 64 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 9%
Student > Bachelor 4 6%
Student > Ph. D. Student 2 3%
Student > Master 2 3%
Student > Doctoral Student 1 2%
Other 1 2%
Unknown 48 75%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 7 11%
Agricultural and Biological Sciences 5 8%
Unspecified 2 3%
Medicine and Dentistry 2 3%
Unknown 48 75%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 September 2011.
All research outputs
#2,901,680
of 3,628,883 outputs
Outputs from Molecular Cancer Therapeutics
#631
of 780 outputs
Outputs of similar age
#40,946
of 60,279 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#10
of 17 outputs
Altmetric has tracked 3,628,883 research outputs across all sources so far. This one is in the 2nd percentile – i.e., 2% of other outputs scored the same or lower than it.
So far Altmetric has tracked 780 research outputs from this source. They receive a mean Attention Score of 4.7. This one is in the 2nd percentile – i.e., 2% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 60,279 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.